




The relative strengths and weaknesses of G1 Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of G1 Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 124% points. The greatest weakness of G1 Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 332%, being 81% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	104,661
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,704
Liabilities, Non-Current	79
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	847
Other Revenues	0
Property and Equipment	510
Research and Development	53,881
Selling, General and Administrative Expense	7,087

Output Variable	Value in 1000 USD
Assets	105,171
Liabilities	11,783
Expenses	60,968
Revenues	0
Stockholders Equity	93,388
Net Income	-60,121
Comprehensive Net Income	-60,121
BaseVar	89,384
ECR before Limited Liability	245%
Economic Capital Ratio	332%